The Blind Common Anabolic Steroid and Aromatase Inhibitor Screening is a comprehensive laboratory analysis designed to detect and quantify commonly encountered anabolic-androgenic steroids and aromatase inhibitors in oral products - pills, tablets, and capsules.
Because this is a blind analysis, there is no need to specify which substance is expected in the sample before submission. Every target compound included in the screening is assessed, and all detected substances are identified and quantified, including samples containing mixtures of multiple compounds.
About the Target Compounds
Anabolic-androgenic steroids are synthetic derivatives of testosterone or related steroid hormones. They interact with androgen receptors and have both anabolic effects, associated with tissue and muscle growth, and androgenic effects. The screened compounds include substances such as oxandrolone, stanozolol, oxymetholone, methandrostenolone, fluoxymesterone, methasterone, mesterolone, methenolone acetate, and 4-chlorodehydromethyltestosterone. Individual compounds differ considerably in their chemical structure, potency, metabolism, and relative anabolic and androgenic activity.
Letrozole, anastrozole, and exemestane are aromatase inhibitors. They inhibit aromatase, the enzyme involved in estrogen biosynthesis, thereby reducing estrogen production. Letrozole and anastrozole are non-steroidal aromatase inhibitors, whereas exemestane is a steroidal aromatase inhibitor. These substances are used medically in hormone-sensitive breast cancer treatment but may also be found in products associated with anabolic steroid use.
Key Features
- Blind screening with no need to declare the expected compound
- Detection of common anabolic steroids and aromatase inhibitors in oral dosage forms
- Identification of mixtures containing multiple target compounds
- Quantification of every detected target compound
- Suitable for pills, tablets, and capsules
- Results reported in mg per pill, tablet, or capsule
- HPLC analytical method
- Average turnaround time of 7 business days
Analysis Parameters
- Target compounds: Letrozole, anastrozole, exemestane, fluoxymesterone, methandrostenolone, oxandrolone, stanozolol, 4-chlorodehydromethyltestosterone, mesterolone, methenolone acetate, methasterone, and oxymetholone
- Other common names and brand names: Femara, Arimidex, Aromasin, Halotestin, Halo, Anavar, Var, Winstrol, Winny, Turinabol, Tbol, Proviron, Superdrol, Anadrol, Anapolon, Methandienone, Dianabol, and Dbol
- Testing method: HPLC
- Detection limit cutoff:
- 2 mg per pill / tablet / capsule
- Letrozole and anastrozole: 0.2 mg pill / capsule
- Result format: mg per pill / tablet / capsule
- Minimum sample amount: One pill / tablet / capsule
- Optimal sample amount: Three pills / tablets / capsules
- Average turnaround time: 7 business days
Optional Additional Analyses
The following optional laboratory services are available:
- Complete Raw Analytical Data
- Batch Variance Testing
- GC–MS Contamination Screening
- Fentanyl Screening
- Heavy Metals Analysis (As, Cd, Pb, Hg)
- Additional Laboratory Report
